Physostigmine impairs short-term memory and causes a "physostigmine syndrome" of sedation and slowed thinking. Long-term memory consolidation remained unaffected, but some subjects experienced emotional distress.
Related Concept Videos
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Physostigmine is a reversible cholinesterase inhibitor.
Its effects on cognitive function and mood require further elucidation.
Purpose of the Study:
To investigate the effects of physostigmine on short-term memory (STM) and long-term memory (LTM) consolidation.
To characterize the behavioral and emotional effects of physostigmine administration.
Main Methods:
A double-blind, placebo-controlled study involving intravenous physostigmine (up to 3 mg) or saline.
Subjects received methscopolamine bromide subcutaneously prior to infusions.
Cognitive function was assessed using digit span tasks for STM and LTM consolidation.
Main Results:
A
physostigmine syndrome
characterized by decreased speech, slowed thoughts, sedation, and nausea, was observed at doses of 1.5-2.0 mg.
Physostigmine significantly impaired STM capacity compared to placebo.
No significant differences were found in LTM consolidation or overall mood, although two subjects in the physostigmine group became tearful and depressed.
Conclusions:
Physostigmine negatively impacts short-term memory and induces a distinct set of behavioral changes.
While not affecting long-term memory consolidation, physostigmine can precipitate negative emotional responses in some individuals.